The GLP-1 receptor in airway inflammation in asthma: a promising novel target?
作者信息
Wu Ashley Y, Peebles R Stokes
机构信息
Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.
Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.
出版信息
Expert Rev Clin Immunol. 2021 Oct;17(10):1053-1057. doi: 10.1080/1744666X.2021.1971973. Epub 2021 Sep 6.
Abstract
摘要
相似文献
1
The GLP-1 receptor in airway inflammation in asthma: a promising novel target?GLP-1受体在哮喘气道炎症中的作用：一个有前景的新靶点？
Expert Rev Clin Immunol. 2021 Oct;17(10):1053-1057. doi: 10.1080/1744666X.2021.1971973. Epub 2021 Sep 6.
2
Glucagon-like peptide 1 signaling inhibits allergen-induced lung IL-33 release and reduces group 2 innate lymphoid cell cytokine production in vivo.胰高血糖素样肽 1 信号抑制变应原诱导的肺 IL-33 释放，并减少体内 2 型先天淋巴细胞细胞因子的产生。
J Allergy Clin Immunol. 2018 Nov;142(5):1515-1528.e8. doi: 10.1016/j.jaci.2017.11.043. Epub 2018 Jan 10.
3
Glucagon-like peptide-1 receptor agonist inhibits aeroallergen-induced activation of ILC2 and neutrophilic airway inflammation in obese mice.胰高血糖素样肽-1 受体激动剂抑制肥胖小鼠气道内嗜酸性粒细胞介素 2 激活和中性粒细胞性气道炎症。
Allergy. 2021 Nov;76(11):3433-3445. doi: 10.1111/all.14879. Epub 2021 May 18.
4
Jiawei Yanghe Decoction attenuate allergic airway inflammation by suppressing group 2 innate lymphoid cells responses.加味羊藿地黄汤通过抑制 2 型固有淋巴细胞的反应来减轻过敏性气道炎症。
J Ethnopharmacol. 2024 May 23;326:117927. doi: 10.1016/j.jep.2024.117927. Epub 2024 Feb 17.
5
A critical role for c-Myc in group 2 innate lymphoid cell activation.c-Myc 在 2 型固有淋巴细胞激活中的关键作用。
Allergy. 2020 Apr;75(4):841-852. doi: 10.1111/all.14149. Epub 2020 Jan 29.
6
Salidroside suppresses group 2 innate lymphoid cell-mediated allergic airway inflammation by targeting IL-33/ST2 axis.红景天苷通过靶向 IL-33/ST2 轴抑制 2 型固有淋巴细胞介导的过敏性气道炎症。
Int Immunopharmacol. 2020 Apr;81:106243. doi: 10.1016/j.intimp.2020.106243. Epub 2020 Feb 15.
7
Cannabinoid receptor 2 engagement promotes group 2 innate lymphoid cell expansion and enhances airway hyperreactivity.大麻素受体 2 的结合促进了 2 型固有淋巴细胞的扩增，并增强了气道高反应性。
J Allergy Clin Immunol. 2022 May;149(5):1628-1642.e10. doi: 10.1016/j.jaci.2021.09.037. Epub 2021 Oct 18.
8
Eosinophils promote effector functions of lung group 2 innate lymphoid cells in allergic airway inflammation in mice.嗜酸性粒细胞促进小鼠过敏性气道炎症中肺群 2 先天淋巴细胞的效应功能。
J Allergy Clin Immunol. 2023 Aug;152(2):469-485.e10. doi: 10.1016/j.jaci.2023.03.023. Epub 2023 Apr 6.
9
Glucagon-like Peptide-1 Receptor Pathway Attenuates Platelet Activation in Aspirin-Exacerbated Respiratory Disease.胰高血糖素样肽-1 受体通路可减轻阿司匹林加重的呼吸道疾病中的血小板活化。
J Immunol. 2023 Dec 15;211(12):1806-1813. doi: 10.4049/jimmunol.2300102.
10
PPARγ enhances ILC2 function during allergic airway inflammation via transcription regulation of ST2.过氧化物酶体增殖物激活受体γ通过对ST2的转录调控增强变应性气道炎症期间2型固有淋巴细胞的功能。
Mucosal Immunol. 2021 Mar;14(2):468-478. doi: 10.1038/s41385-020-00339-6. Epub 2020 Aug 18.
引用本文的文献
1
The therapeutic potential of glucagon-like peptide-1 receptor analogs for neuroinflammation in the setting of asthma.胰高血糖素样肽-1受体类似物在哮喘背景下对神经炎症的治疗潜力。
Explor Asthma Allergy. 2025;3. doi: 10.37349/eaa.2025.100967. Epub 2024 Dec 17.
2
Clinical and mechanistic advancements in aspirin exacerbated respiratory disease.阿司匹林加重呼吸道疾病的临床与机制进展
J Allergy Clin Immunol. 2025 May;155(5):1411-1419. doi: 10.1016/j.jaci.2025.03.006. Epub 2025 Mar 18.
3
Potential Use of GLP-1 and GIP/GLP-1 Receptor Agonists for Respiratory Disorders: Where Are We at?胰高血糖素样肽-1（GLP-1）及胃抑肽/胰高血糖素样肽-1（GIP/GLP-1）受体激动剂在呼吸系统疾病中的潜在应用：我们目前进展如何？
Medicina (Kaunas). 2024 Dec 9;60(12):2030. doi: 10.3390/medicina60122030.
4
Comparative estimate of glucose-lowering therapies on risk of incident pneumonia and severe sepsis: an analysis of real-world cohort data.降糖疗法对新发肺炎和严重脓毒症风险的比较评估：一项真实世界队列数据分析
Thorax. 2024 Dec 23;80(1):32-41. doi: 10.1136/thorax-2024-221906.
5
Antidiabetic Medication and Asthma Attacks.抗糖尿病药物与哮喘发作
JAMA Intern Med. 2025 Jan 1;185(1):16-25. doi: 10.1001/jamainternmed.2024.5982.
6
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of developing cancer-related lymphedema following axillary lymph node dissection (ALND).胰高血糖素样肽-1受体激动剂（GLP-1 RAs）可能会降低腋窝淋巴结清扫术（ALND）后发生癌症相关淋巴水肿的风险。
Front Pharmacol. 2024 Sep 4;15:1457363. doi: 10.3389/fphar.2024.1457363. eCollection 2024.
7
Body Weight and Allergic Asthma: A Narrative Review.体重与过敏性哮喘：一篇叙述性综述。
J Clin Med. 2024 Aug 15;13(16):4801. doi: 10.3390/jcm13164801.
8
Curbing the Obesity Epidemic: Should GLP-1 Receptor Agonists Be the Standard of Care for Obesity?遏制肥胖流行：GLP-1 受体激动剂是否应该成为肥胖治疗的标准？
Curr Cardiol Rep. 2024 Sep;26(9):1011-1019. doi: 10.1007/s11886-024-02097-4. Epub 2024 Jul 20.
9
Liraglutide pretreatment attenuates sepsis-induced acute lung injury.利拉鲁肽预处理可减轻脓毒症引起的急性肺损伤。
Am J Physiol Lung Cell Mol Physiol. 2023 Sep 1;325(3):L368-L384. doi: 10.1152/ajplung.00041.2023. Epub 2023 Jul 25.
10
Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent.胰高血糖素样肽-1：一种多效抗炎剂。
Front Immunol. 2023 May 17;14:1148209. doi: 10.3389/fimmu.2023.1148209. eCollection 2023.
本文引用的文献
1
Glucagon-like peptide-1 receptor agonist inhibits aeroallergen-induced activation of ILC2 and neutrophilic airway inflammation in obese mice.胰高血糖素样肽-1 受体激动剂抑制肥胖小鼠气道内嗜酸性粒细胞介素 2 激活和中性粒细胞性气道炎症。
Allergy. 2021 Nov;76(11):3433-3445. doi: 10.1111/all.14879. Epub 2021 May 18.
2
Use of GLP1RAs and occurrence of respiratory disorders: A meta-analysis of large randomized trials of GLP1RAs.GLP1RA 类药物的使用与呼吸障碍的发生：GLP1RA 大型随机试验的荟萃分析。
Clin Respir J. 2021 Jul;15(7):847-850. doi: 10.1111/crj.13372. Epub 2021 Apr 19.
3
Dysregulated Metabolism in the Pathophysiology of Non-Allergic Obese Asthma.非过敏性肥胖哮喘病理生理学中的代谢失调
J Asthma Allergy. 2021 Mar 4;14:179-186. doi: 10.2147/JAA.S282284. eCollection 2021.
4
Glucagon-like peptide 1 receptor (GLP-1R) agonist relieved asthmatic airway inflammation via suppression of NLRP3 inflammasome activation in obese asthma mice model.胰高血糖素样肽 1 受体（GLP-1R）激动剂通过抑制肥胖哮喘小鼠模型中 NLRP3 炎性体的激活缓解哮喘气道炎症。
Pulm Pharmacol Ther. 2021 Apr;67:102003. doi: 10.1016/j.pupt.2021.102003. Epub 2021 Feb 12.
5
GLP-1 Receptor Signaling Differentially Modifies the Outcomes of Sterile vs Viral Pulmonary Inflammation in Male Mice.GLP-1 受体信号传导对雄性小鼠无菌性与病毒性肺部炎症的结局有差异修饰作用。
Endocrinology. 2020 Dec 1;161(12). doi: 10.1210/endocr/bqaa201.
6
Asthma Exacerbations in Patients with Type 2 Diabetes and Asthma on Glucagon-like Peptide-1 Receptor Agonists.2 型糖尿病合并哮喘患者使用胰高血糖素样肽-1 受体激动剂后哮喘加重。
Am J Respir Crit Care Med. 2021 Apr 1;203(7):831-840. doi: 10.1164/rccm.202004-0993OC.
7
Intratracheal GLP-1 receptor agonist treatment up-regulates mucin via p38 and exacerbates emphysematous phenotype in mucus hypersecretory obstructive lung diseases.气管内 GLP-1 受体激动剂治疗通过 p38 上调粘蛋白，并在粘液高分泌阻塞性肺部疾病中加重肺气肿表型。
Biochem Biophys Res Commun. 2020 Apr 2;524(2):332-339. doi: 10.1016/j.bbrc.2020.01.081. Epub 2020 Jan 26.
8
Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients.长期观察研究 GLP-1R 激动剂对糖尿病患者肺功能的影响。
Respir Med. 2019 Jul-Aug;154:86-92. doi: 10.1016/j.rmed.2019.06.015. Epub 2019 Jun 18.
9
IL33: Roles in Allergic Inflammation and Therapeutic Perspectives.IL33：变应性炎症中的作用及治疗展望。
Front Immunol. 2019 Mar 4;10:364. doi: 10.3389/fimmu.2019.00364. eCollection 2019.
10
Glucagon-like peptide-1 receptor activation alleviates lipopolysaccharide-induced acute lung injury in mice via maintenance of endothelial barrier function.胰高血糖素样肽-1 受体激动剂通过维持内皮屏障功能减轻脂多糖诱导的小鼠急性肺损伤。
Lab Invest. 2019 Apr;99(4):577-587. doi: 10.1038/s41374-018-0170-0. Epub 2019 Jan 18.
Zotero 插件